← Oncology Approval Tracker

FDA DECISION ·

Epkinly

epcoritamab-bysp · Genmab

Accelerated approvalNew or expanded indicationFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Nov 18, 2025

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with relapsed or refractory follicular lymphoma after two or more systemic treatment lines.

LAMPGEN ANALYSIS

Why it matters

The CD20×CD3 bispecific added a later-line subcutaneous treatment option in follicular lymphoma. The FDA granted traditional approval for this use in November 2025.

What research teams should watch

Reconcile prior lines and program the follicular lymphoma-specific step-up schedule, with escalation plans for fever and neurologic symptoms.

PRIMARY RECORDS

Sources